What is Xeris Biopharma Holdings?
Xeris Biopharma Holdings, Inc. operates as a commercial-stage biopharmaceutical entity focused on the development, manufacturing, and commercialization of high-impact therapies. By leveraging proprietary formulation technologies, the company enhances the convenience and efficacy of existing treatments, thereby improving patient outcomes. Its market position is defined by a diversified portfolio that bridges the gap between complex pharmaceutical science and practical clinical application. As a key player in the life sciences sector, Xeris continues to refine its therapeutic options, ensuring that its product suite remains at the forefront of medical innovation and patient-centric care.
How much funding has Xeris Biopharma Holdings raised?
Xeris Biopharma Holdings has raised a total of $663.4M across 12 funding rounds:
Series A
$1.8M
Debt
$2.3M
Series B
$7.3M
Series C
$81M
Stock Offering
$98.3M
Stock Offering
$55.6M
Debt
$85M
Multiple Rounds
$152.1M
Share Placement
$30M
Debt
$150M
Series A (2011): $1.8M with participation from Undisclosed
Debt (2013): $2.3M led by Undisclosed
Series B (2014): $7.3M supported by Undisclosed
Series C (2018): $81M featuring Deerfield Management, Asahi-Kasei Corporation, Wild Basin Investments, McNair Group, Merieux Developpement, Sabby Management, Palmetto Partners, Redmile Group, and Bay City Capital
Stock Issuance/Offering (2018): $98.3M backed by Undisclosed
Stock Issuance/Offering (2019): $55.6M with participation from Undisclosed
Debt (2019): $85M led by Oxford Finance Corporation and Silicon Valley Bank
Stock Issuance/Offering (2020): $42.7M supported by Undisclosed
Debt (2020): $86.3M featuring Undisclosed
Stock Issuance/Offering (2020): $23.2M backed by Undisclosed
Share Placement (2022): $30M, investors not publicly disclosed
Debt (2022): $150M led by Hayfin
Key Investors in Xeris Biopharma Holdings
Hayfin
Hayfin Capital Management is a prominent European alternative asset manager that provides flexible financing solutions, including direct lending and special opportunities, to support high-growth enterprises.
Oxford Finance Corporation
Oxford Finance is a specialty finance firm dedicated to providing tailored capital solutions to companies operating within the healthcare and life sciences sectors.
Silicon Valley Bank
Silicon Valley Bank is a premier financial institution offering comprehensive banking and investment services specifically designed to support the unique needs of the innovation economy.
What's next for Xeris Biopharma Holdings?
With the recent capital injection, Xeris Biopharma Holdings is well-positioned to execute its long-term growth strategy, which includes expanding its commercial footprint and deepening its research and development capabilities. The company is expected to prioritize the scaling of its manufacturing infrastructure and the potential expansion of its therapeutic indications. By maintaining a disciplined approach to capital allocation and strategic partnerships, Xeris aims to solidify its market leadership, drive sustainable revenue growth, and deliver long-term value to stakeholders while continuing to address the evolving demands of the global healthcare ecosystem.
See full Xeris Biopharma Holdings company page
